Maynard Um
-
-
-
-
-
-
-
Pharvaris B.V. (PHVS) PT Raised to $75 at Oppenheimer
-
-
-
-
-
-
-
Pharvaris publishes review on bradykinin B2 receptor as therapy target
-
-
-
-
-
-
-
Pharvaris B.V. (PHVS) PT Lowered at RBC Capital; 'CHAPTER-3 Pivotal Topline In Focus For 3Q'
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Pharvaris B.V. (PHVS)
-
-
-
-
-
-
-
Pharvaris B.V.'s (PHVS) Improving Profile Can Send Shares Up >$30s - Citizens
-
-
-
-
-
-
-
Pharvaris (PHVS) to Present Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Pharvaris B.V. (PHVS)
-
455,448 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

